Public Market Listing
4506TSE
Live quotes, historical charts, and market capitalization for Sumitomo Pharma are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(8 total)
8Total Assets
3Approved
2Phase 3 / Filed
3Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | dopamineSmall molecule | Parkinson's Disease | |
Eslicarbazepine acetate(Aptiom) | Approved | Voltage-gated sodium channelSmall molecule | Epilepsy |
| Approved | Dopamine D2/D3 receptor + 5-HT7 receptor · Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
| Phase 3 | norepinephrine precursorSmall molecule | Parkinson's Disease | |
| Phase 3 | TAAR1 (trace amine-associated receptor 1)Small molecule | Schizophrenia | |
| Phase 1/2 | Allogeneic iPSC-derived dopaminergic progenitor cellsCell therapy | Parkinson's Disease | |
| Phase 1/2 | Menin-KMT2A protein-protein interactionSmall molecule | Acute Myeloid Leukemia | |
| Phase 1 | Undisclosed / early pipelineSmall molecule | Major Depressive DisorderSchizophrenia |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.